Letter from Michael Rodell Vice President Hyland to Charles Carman and Louis M. Aledort National Hemophilia Foundation which details practices by Hyland to exclude high-risk groups from its plasma collection and also acknowledges concern over the reported incidence of AIDS among hemophiliacs. Discusses the difficulties with questioning and identifying homosexual donors. A letter from Michael Rodell of Hyland Therapeutics Division Travenol Laboratories to Charles Carman and Louis M. Aledort of the National Hemophilia Foundation. The letter discusses Hyland Therapeutics response to the National Hemophilia Foundations Scientific Advisory Council recommending the exclusion from plasma donations of certain groups of individuals considered to be in a high risk category relative to AIDS.